The trial demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate ...

The global hyperphosphatemia treatment market grew from $3.57 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the ...

The goal of hyperphosphatemia treatment should be to reduce serum phosphorus to ?5.5mg/dL (or closer to normal levels) and alleviate negative clinical outcomes for patients with CKD, including ...

In this video, Kevin Martin, MD, discusses treatment options available to patients with hyperphosphatemia.

About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD).

In this video, Kevin Martin, MD, discusses new and emerging technologies in the field of hyperphosphatemia.

Xphozah ® (tenapanor) is now available to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to ...

RELATED: Keryx Submits NDA for Hyperphosphatemia Drug, Zerenex Ferric Citrate is also being developed as a treatment for iron deficiency anemia in patients with Stage 3– 5 non-dialysis dependent ...

Among the 184 survivors of 24-hour CRRT, hyperphosphatemia was associated with a significant 2.2 times and 2.6 times increased risk of death at 28 days and 90 days, respectively.